Are you Dr. Foon?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 46 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1 Breakthrough Way
Las Vegas, NV 89135Phone+1 702-822-5373Fax+1 702-944-0451
Summary
- Dr. Kenneth Foon, MD is an oncologist in Las Vegas, Nevada. He is currently licensed to practice medicine in Nevada, New Jersey, and Florida.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1980- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1977 - 1979
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1976 - 1977
University of California (San Diego) Medical CenterInternship, Internal Medicine, 1972 - 1973
Wayne State University School of MedicineClass of 1972
Certifications & Licensure
CA State Medical License 1975 - 2021
NJ State Medical License 2010 - 2019
NV State Medical License 2008 - 2011
FL State Medical License 2008 - 2010
PA State Medical License 2003 - 2008
OH State Medical License 1999 - 2003
MD State Medical License 1974 - 1994- Join now to see all
Publications & Presentations
PubMed
- 79 citationsRadioimmunodetection of Cutaneous T-Cell Lymphoma with 111In-Labeled T101 Monoclonal AntibodyJorge A. Carrasquillo, Paul A. Bunn, A.M. Keenan, James C. Reynolds, Robert W. Schroff
The New England Journal of Medicine. 1986-09-11 - 1272 citationsIDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaDavid G. Maloney, Antonio J. Grillo-Lopez, Christine A. White, David Bodkin, Russell J. Schilder
Blood. 1997-09-15 - 181 citationsT gamma-lymphoproliferative disease and related disorders in humans and experimental animals: a review of the clinical, cellular, and functional characteristicsCraig W. Reynolds, Kenneth A. Foon
Blood. 1984-12-01
Grant Support
- Core--Protocol Specific ResearchNational Cancer Institute2004–2008
- Ganglioside GD2 As Target For Immunotherapy In MelanomaNational Cancer Institute2003–2004
- Southwest Oncology GroupNational Cancer Institute1999–2001
- Antiidiotype Vaccine With IL2 For Advanced MelanomaNational Cancer Institute2000
- Antiidiotype Vaccine With IL2 For Advanced MelanomaNational Cancer Institute1998
- New Therapeutic Approaches To Breast CancerNational Cancer Institute1995–1997
- Anti Idiotype Vaccine For Breast CancerNational Cancer Institute1995–1997
- Southwest Oncology GroupNational Cancer Institute1994–1997
- Comparison Of Alum And Qs 21 Based Anti ID VaccinesNational Cancer Institute1996
- Planning Grants For Prospective Cancer CentersNational Cancer Institute1995–1996
- Monoclonal Antibody Therapy Of GI CancersNational Cancer Institute1992–1993
- Monoclonal Antibody Therapy Of GI CancersNational Cancer Institute1992
- Momoclonal Antibody Therapy Of GI CancersNational Cancer Institute1991–1992
- Validation Of An In Vitro Drug Sensitivity Assay For CLLNational Cancer Institute1990
- Mechanisms Of IFN Action In Hairy-Cell LeukemiaNational Cancer Institute1988
- Mechanism Of IFM Action In Hairy-Cell LeukemiaNational Cancer Institute1987
- Mechanisms Of IFN Action In Hairy-Cell LeukemiaNational Cancer Institute1986–1987
